Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
This Item 8.01 discloses the issuance and sale of approximately $832.6 million in commercial mortgage pass-through certificates (BANK5 2026-5YR22) by Wells Fargo Commercial Mortgage Securities, Inc., including publicly offered certificates ($735.8M) and privately offered certificates ($96.8M), along with detailed credit risk retention compliance under Regulation RR. While this is a material securitization transaction affecting the registrant's capital structure and investor base, it does not fit neatly into the standard 8-K event taxonomy (not an M&A activity, earnings release, or other specifically enumerated event type), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 1.01
The filing discloses entry into a material definitive agreement—the Pooling and Servicing Agreement dated May 1, 2026, establishing Wells Fargo Commercial Mortgage Trust 2026-5C9 and the issuance of Commercial Mortgage Pass-Through Certificates backed by 29 fixed-rate mortgage loans and subordinate interests in 2 commercial mortgage loans. This represents a securitization transaction involving the creation of an issuing entity and transfer of material assets, which constitutes M&A-like activity requiring Item 1.01 disclosure. The subsequent transfer of The Towers at Cupertino City Center Mortgage Loan to the BANK5 2026-5YR22 securitization further evidences material asset disposition activity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of Carlyle Secured Lending's 2026 Annual Meeting of Stockholders held on June 9, 2026, including voting outcomes for the election of two Class I directors (Linda Pace and William H. Wright II) and ratification of Ernst & Young LLP as independent auditor. The filing presents detailed vote tallies (For/Withhold/Broker Non-Votes) for each proposal, all of which were approved by requisite vote. This is a standard shareholder vote results disclosure material to investors' understanding of corporate governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from a Special Meeting held on June 9, 2026. The filing reports the final voting tallies (26,328,719 for, 7,457,315 against, 2,023,401 abstain) on a proposal to authorize the Company to issue shares below net asset value over the next 12 months. The proposal was approved by the requisite vote. This is material because authorization to issue dilutive equity at below-NAV prices directly affects shareholder value and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Nurix disclosed updated Phase 1a/1b clinical trial data for its lead BTK degrader bexobrutideg (NX-5948) in CLL/SLL patients, presented at EHA2026, including expanded safety findings across 142 patients and an 83% objective response rate in relapsed/refractory patients, along with new Phase 1b cohort data in earlier-line treatment settings.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Airbnb's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing presents voting outcomes on seven proposals: election of three Class III directors (Blecharczyk, Lin, Manyika), ratification of PwC as auditor, advisory vote on named executive officer compensation, and four stockholder proposals (all defeated). The detailed vote tallies for each proposal are the core content of the disclosure, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance outcomes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports the outcomes of three proposals voted on at Caesars Entertainment's June 9, 2026 Annual Meeting: election of 11 directors (all elected by majority vote), advisory approval of named executive officer compensation (85.7% approval), and ratification of Deloitte & Touche LLP as independent auditor (99.8% approval). The detailed vote tallies and percentages are the core content of the disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 7.01
Summit Therapeutics withdrew a previously announced underwritten public offering effective June 10, 2026 due to market conditions. While the withdrawal itself is disclosed under Item 7.01 (Other Events), the cancellation of a planned capital raise signals material market or financial stress that would affect investor assessment of the company's liquidity and strategic position. This does not fit neatly into the dilutive_issuance category (which covers completed or announced offerings) but represents a material change in the company's financing plans.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-11
Item 5.02
Shareholders approved the Fifth Amended and Restated 2019 Equity Incentive Plan, increasing authorized shares by 565,000 for equity compensation purposes to officers and directors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
Weatherford held a Special Court-Convened Meeting and 2026 Annual General Meeting on June 11, 2026, with voting results on six director elections, auditor ratification, executive compensation approval, equity plan approval, and a failed redomestication proposal from Ireland to Texas that did not achieve the required 75% threshold.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Caribou Biosciences announced clinical trial data from two ongoing phase 1 trials: ANTLER for vispa-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (82% ORR, 67% CR) and CaMMouflage for CB-011 in relapsed/refractory multiple myeloma (92% ORR, 83% ≥CR). The data, presented at the EHA 2026 Annual Meeting, demonstrates progress toward planned phase 3 trials and is material to investors assessing the company's pipeline advancement and regulatory pathway.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 7.01
Philip Morris announced a regular quarterly dividend of $1.47 per share via press release on June 11, 2026, disclosed under Item 7.01 (Regulation FD Disclosure). While dividend declarations are routine corporate actions, they are material to shareholders as they affect total shareholder return and cash flow expectations. This does not fit the earnings_release category (which typically reports financial results) nor any other specific event type in the taxonomy, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
The filing discloses a press release announcing The Lovesac Company's financial results for the first quarter of fiscal year 2027 (ended May 3, 2026), filed under Item 2.02 (Results of Operations and Financial Condition). This is a classic earnings release disclosure, which is material to investors as it provides periodic financial performance information.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
C4 Therapeutics disclosed positive Phase 1 trial data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma, presented via a poster at EHA 2026 Congress and accompanied by a press release. This clinical trial progress is material to the company's pipeline prospects and would affect a reasonable investor's assessment of the registrant's development stage and competitive position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
The filing discloses an earnings press release for the quarterly period ended May 2, 2026, issued on June 11, 2026, and furnished as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02, which is material to investors as it provides financial results and operational performance for the period.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Ovid Therapeutics' annual meeting of stockholders held on June 10, 2026. The filing presents voting results for three proposals: (1) election of director Jeremy M. Levin (87.2M votes for, 8.5M withheld), (2) advisory approval of named executive officer compensation (84.5M for, 8.9M against), and (3) ratification of KPMG LLP as auditor (130.8M for, 32.5K against). These are routine annual meeting matters that materially inform shareholders about governance and management approval.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-11
Item 1.01
Blue Owl Credit Income Corp. completed a $500 million debt offering on June 11, 2026, pursuant to a Purchase Agreement dated June 8, 2026, with proceeds to be used to pay down existing indebtedness. This material capital structure event was disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation), representing a significant refinancing or debt restructuring transaction.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-11
Item 5.02
The filing discloses amendments to compensatory arrangements for two named executives: Lachlan K. Murdoch (Executive Chair and CEO) and Steven Tomsic (CFO). The Committee and Board approved increases in target annual bonuses and equity awards for both executives, as well as extensions of their employment terms through June 30, 2030. This is a classic executive compensation disclosure under Item 5.02(e), distinct from a departure or appointment, and is material to investors assessing executive incentive structures and retention.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-11
Item 5.02
Eric Park was appointed Chief Accounting Officer effective June 8, 2026, assuming the role of principal accounting officer. While the disclosure also includes compensatory arrangements (base salary increase to $300,000, bonus target of $200,000, and a $175,000 PRSU award), the principal disclosed action is the appointment itself. The appointment of a principal accounting officer is material to investors as it affects the registrant's financial reporting oversight and governance structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of IMAX Corporation's 2026 Annual General Meeting of Shareholders held on June 10, 2026. The filing presents voting results on three matters: election of ten directors, appointment of PricewaterhouseCoopers LLP as independent auditors, and an advisory say-on-pay vote on Named Executive Officer compensation. All three outcomes are material to shareholders' understanding of corporate governance and management accountability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-11
Item 3.01
GoHealth received a written notice from Nasdaq on June 9, 2026 determining to delist the Company's Class A common stock (GOCO) from Nasdaq, effective June 16, 2026. The delisting was based on the Chapter 11 bankruptcy filing, concerns about residual equity interests, and failure to maintain the $35 million minimum market value requirement under Nasdaq Listing Rule 5550(b)(2). This is a direct and material delisting event that removes the company's primary listing venue.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the final results of voting at Magnite's 2026 annual stockholder meeting held on June 8, 2026. The filing presents voting tallies for four proposals: election of three Class III directors (Paul Caine, Doug Knopper, David Pearson), ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, and advisory frequency vote on future compensation votes. All proposals passed. This is a material event as shareholder meeting outcomes affect corporate governance and investor confidence.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-11
Item 4.01
The filing discloses the dismissal of BDO USA, P.C. as the Company's independent registered public accounting firm effective June 5, 2026, and the simultaneous appointment of Deloitte & Touche LLP as the new auditor. This is a classic auditor change under Item 4.01. The materiality is heightened by the disclosure of material weaknesses in internal control over financial reporting in both 2024 and 2025, including adverse audit opinions and ongoing control deficiencies in revenue, inventory, and segregation of duties.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the final results of Limbach Holdings' June 9, 2026 annual meeting of stockholders, including voting outcomes on four proposals: election of three Class A directors (Horowitz, Alvarado, Dugan), non-binding advisory approval of named executive officer compensation, frequency of say-on-pay votes, and ratification of Crowe LLP as independent auditor. The detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core content, making this a textbook shareholder_vote_results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Yext held its annual meeting of stockholders on June 10, 2026, at which shareholders voted on four proposals: election of Class III directors (Daniel Englander and Andrew Sheehan), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the 2016 Equity Incentive Plan, as amended, restated and extended.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Acadian Asset Management held its Annual Meeting on June 11, 2026, with shareholders voting on four proposals: election of five directors, ratification of KPMG LLP as independent auditor, advisory vote on executive compensation, and approval of the 2026 Equity Incentive Plan. The filing discloses detailed voting tallies for all four proposals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Pacira BioSciences held its Annual Meeting of Stockholders on June 9, 2026, with detailed voting results disclosed for five proposals: election of three Class III directors (including contested nominees), ratification of KPMG LLP as auditor, advisory vote on named executive officer compensation, and approval of two equity plans.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-11
Item 5.02
Stockholders approved an Amended and Restated 2014 Employee Stock Purchase Plan (ESPP) with an increase of 800,000 newly reserved shares, a material compensatory arrangement affecting equity incentives available to employees.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Alight's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents detailed vote tallies for six proposals: election of Class II directors (Fradin, Lopes, Massey), ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, board declassification amendment, officer liability limitation amendment, and reverse stock split authorization. All proposals passed. The disclosure is material as it documents stockholder approval of significant corporate governance changes (board declassification, officer liability protection) and strategic actions (reverse split authorization).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
Lennar Corporation issued a press release on June 11, 2026 announcing results of operations for the second quarter ended May 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Western Alliance Bancorporation's Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting outcomes for three proposals: election of thirteen directors, advisory vote on executive compensation, and ratification of RSM US LLP as independent auditor. All three proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from Ares Management's June 8, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: (1) election of 11 directors to one-year terms, with detailed vote tallies for each nominee (FOR, AGAINST, ABSTAIN, BROKER NON-VOTES), and (2) ratification of Ernst & Young LLP as independent auditor. This is a textbook Item 5.07 disclosure and is material to investors as it confirms board composition and auditor ratification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 1.01
The filing discloses entry into a material definitive agreement—a Second Amendment to the Credit Agreement with Wells Fargo Bank extending the maturity date from June 25, 2027 to September 10, 2028. While this is a credit facility amendment rather than a traditional M&A transaction, it represents a material modification to the Company's financing arrangements that would affect a reasonable investor's assessment of liquidity and financial obligations. The extension of maturity by over a year is a substantive change to the capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from LivaNova's 2026 Annual General Meeting held on June 10, 2026. The filing presents detailed voting tallies for all 10 resolutions considered, including director elections, say-on-pay, auditor ratification, and share authorization matters. This is a quintessential Item 5.07 disclosure and is material as it documents shareholder approval of key governance and compensation matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
BeOne Medicines held its Annual Meeting on June 11, 2026, with shareholders voting on 20 proposals including director elections, compensation plan amendments (Fifth Amended and Restated 2016 Share Option and Incentive Plan and Sixth Amended and Restated 2018 Employee Share Purchase Plan), and capital allocation matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This 8-K Item 5.07 discloses the results of Coursera's 2026 Annual Meeting of Stockholders held on June 10, 2026, including voting outcomes on three proposals: election of Class II directors (McCarthy, Ng, Paterson), advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. The filing presents final vote tallies for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure describes the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of New York. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the disclosure is primarily informational and regulatory in nature—explaining the structure, joint and several liability framework, and reporting methodology for consolidated obligations rather than announcing a specific new debt issuance event. The absence of a Schedule A with specific issuance details and the emphasis on general policies and disclaimers suggest this is a routine periodic disclosure of the Bank's debt issuance program rather than a discrete material event triggering Item 2.03.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting vote results. The filing reports the outcomes of four proposals voted on at the June 10, 2026 annual meeting: election of eight directors (approved), ratification of Grant Thornton LLP as auditors (approved), advisory vote on executive compensation (failed/not approved), and amendment to by-laws on quorum requirements (approved). The failure of Proposal 3 (say-on-pay) is material to investors as it signals shareholder dissatisfaction with executive compensation practices.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from the June 10, 2026 annual meeting, reporting the election of five directors (John Swallow, Grant Brackebusch, Kevin Shiell, Rich Beaven, and Carolyn Turner) and ratification of Assure, CPA, LLC as independent auditor. The filing presents detailed vote tallies for each proposal, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from Acushnet's June 8, 2026 Annual Meeting of Stockholders, covering three proposals: election of eight directors, non-binding advisory vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents final vote tallies for each proposal, which is the core content of Item 5.07 and constitutes a material event affecting investor understanding of corporate governance and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from the June 5, 2026 annual meeting. The filing reports final voting tallies for four proposals: director elections (with the notable detail that two nominees—Lin and Taylor—failed to achieve majority votes but were retained by the Board following an administrative error explanation), auditor ratification, say-on-pay (which failed), and say-on-pay frequency. The say-on-pay rejection and the director election controversy (particularly the Board's decision to retain Lin and Taylor despite failing to win majority votes) are material to investors assessing governance and compensation practices.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 7.01
HF Foods announced adoption of a "limited duration stockholder rights plan" (a poison pill), which is a material defensive measure that affects shareholder rights and capital structure. While not fitting neatly into the standard taxonomy categories (not M&A, not exec-related, not financial restatement), adoption of a rights plan is material to investors as it signals potential takeover defense and alters voting dynamics. This is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a more specific Item, supporting classification as other_material.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-11
Item 5.02
The Board appointed three new independent directors—Robert Fotheringham, Zhenlong Jiao, and Henoc Muamba—on June 9, 2026, expanding the Board from three to six members. The new directors were assigned to lead key committees (Audit, Compensation, and Nominating and Corporate Governance), materially strengthening the company's governance structure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 8.01
On June 9, 2026, the Board adopted formal committee charters for the Audit, Compensation, and Nominating and Corporate Governance committees, appointed committee members, and adopted a Code of Ethics and insider trading policy. These governance framework and compliance actions materially enhance the company's corporate governance posture.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-11
Item 3.01
YHN Acquisition I Ltd received a Nasdaq deficiency notification on June 10, 2026, stating non-compliance with the minimum total holders requirement (400 holders) under Nasdaq Listing Rule 5450(a)(2). The company has 45 calendar days to submit a compliance plan and up to 180 days to evidence compliance, with the alternative of transferring to Nasdaq Capital Market. This is a classic delisting risk disclosure under Item 3.01, material to investors as it threatens the company's continued listing status.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-11
Item 5.02
The filing discloses the appointment of two new officers effective June 1, 2026: Andrew MacLeod as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) and Robert Givens as Secretary. While the section also includes Michael Ssebugwawo's resignation from CFO and other officer roles, the principal disclosed action centers on filling those critical positions with new appointees. The appointments of a CFO and Secretary are material to investors' assessment of the company's governance and financial reporting structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Cardiff Lexington entered into a common stock purchase agreement with an institutional investor committing to purchase up to $25 million (expandable to $75 million) of common stock at a discount to market price (97% of VWAP), with the Company retaining discretion to direct purchases over 36 months. This is a classic "equity line of credit" or PIPE-like arrangement that creates substantial dilution risk to existing shareholders, particularly given the discount pricing mechanism and the Company's unilateral control over timing and amount of issuances.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 3.02
The filing discloses an unregistered private placement of 285,768 shares of Series A Convertible Preferred Stock under Rule 506(b) of Regulation D, generating $2.84 million in gross proceeds during June 2–10, 2026. This is a classic dilutive issuance of equity securities exempt from registration, with 12.6 million shares of the preferred stock now outstanding. The convertible nature and substantial capital raise make this material to investors assessing ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the results of Carlyle Credit Solutions' 2026 Annual Meeting of Stockholders held on June 9, 2026, including voting outcomes for the election of two Class I directors (Linda Pace and William H. Wright II) and ratification of Ernst & Young LLP as independent auditor. The filing presents detailed vote tallies showing all proposals were approved by requisite margins, which is the core purpose of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-11
Item 5.02
Bryan D. Coy resigned as Executive Vice President and Chief Financial Officer on June 10, 2026. While the filing also discloses the appointment of Brett A. Correia as interim CFO, the primary disclosed action centers on Coy's departure from a senior executive role. The departure of a CFO is material to investors assessing management continuity and financial oversight. The severance arrangement (accelerated vesting of 21,327 restricted shares and up to six months of base salary) further underscores the significance of this executive departure.
View raw filing on EDGAR →